Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2011 Financial Results on Thursday, March 1, 2012
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will host a conference call and live audio webcast at 8:00 a.m. ET on Thursday, March 1, 2012 to provide a business update and discuss its fourth-quarter and full-year 2011 financial and operational results.
Investors and the public are invited to listen to a live webcast of the call. If you are unable to join the live call, an archived version of the webcast will be available until March 15, 2012. The conference call can be accessed as follows:
|
CONFERENCE CALL INFORMATION |
|||||||||||
| TO PARTICIPATE LIVE: | TO LISTEN TO A REPLAY: | ||||||||||
|
Date: |
March 1, 2012 |
Available until: |
March 15, 2012 |
||||||||
|
Time: |
8:00 am ET |
Toll-free (U.S.) Dial in # : |
(877) 660-6853 |
||||||||
|
International Dial in # : |
(201) 612-7415 |
||||||||||
|
Toll-free (U.S.) Dial in # : |
877) 407-8033 |
Replay passcode: |
|||||||||
|
International Dial in # : |
(201) 689-8033 |
Account #: |
286 |
||||||||
|
Conference ID #: |
390060 |
||||||||||
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms – Lymphoseek®, AZD4694 and RIGScanTM – to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson,
614-822-2330
Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released February 27, 2012